Navigation Links
The Leukemia & Lymphoma Society Calls for Blood Cancer Research Program at the Department of Defense
Date:6/18/2009

WASHINGTON, June 18 /PRNewswire-USNewswire/ -- George Dahlman, senior vice president of public policy for The Leukemia & Lymphoma Society (LLS), testified today before the U.S. Senate Subcommittee on Defense Appropriations, calling for funding for a dedicated, stand-alone blood cancer research program at the Department of Defense (DoD).

The Institute of Medicine (IOM) has determined that several blood cancers, including chronic lymphocytic leukemia (CLL), lymphoma and multiple myeloma, are associated with exposure to chemical and biological agents from the Vietnam and two Gulf Wars. IOM has identified the need to begin a special research program that is responsive to the needs of military personal and veterans.

LLS specifically called for the funding of a collaborative public-private effort between the U.S. Military Cancer Institute, LLS and a blue ribbon panel of scientific academicians.

The USMCI has over 9 million electronic medical records detailing the health histories of service men and women and their families. The military also has serum and tissue specimens from these individuals stored as a routine step in their health care. These records and samples, together, provide a unique base that can power blood cancer research relevant to the military environment and lifestyle in a way that is not possible for any other population.

"A joint effort, tapping the expertise of both USMCI and LLS, represents a unique opportunity to identify valuable research opportunities and state-of-the-art technology that can address significant questions on the origins and diagnosis of blood cancers," according to Dahlman.

"DoD research on blood cancers addresses the importance of preparing for civilian and military exposure to the weapons being developed by several hostile nations and to aid in the march to more effective treatment for all who suffer from these diseases," Dahlman said. "This request clearly has merit for inclusion in the fiscal 2010 legislation."

The Department of Defense already hosts research programs for breast and prostate cancers and, from 2001-2007, hosted a chronic myelogenous leukemia (CML) research program funded at $30 million over the six year period.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society (R) (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET. www.lls.org.

    Contact: Patrick Dyer
    patrick.dyer@lls.org


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Taking Aim at Relapse of Leukemia in Kids
2. Cepheid Announces European Release of Improved Test for BCR-ABL Chromosomal Translocation Associated With Chronic Myelogenous Leukemia (CML)
3. Study IDs benefit of donor SCT for adults with acute myeloid leukemia
4. Donor Stem-Cell Transplant Best For Acute Myeloid Leukemia
5. Loyola fellow receives Amgen grant to study treatments for older leukemia patients
6. 5 Spanish centers join a study for a new leukemia and lymphoma treatment technique
7. Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia and Ovarian Cancer Will Be Presented at ASCO
8. Cole Foundation injects $2.5 million to bolster leukemia research
9. Leukemia Risk From MS Drug May Be Up
10. Risk of Leukemia with Multiple Sclerosis Drug Higher Than Thought
11. Researchers find drug that inhibits acute leukemia cell growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... Public relations pros work ... a variety of business channels. , While many results are clear, much of PR ... program. , When it comes to measurement, firms should always take an all-inclusive ...
(Date:3/28/2017)... ... 2017 , ... Oily skin is a common and unwelcomed occurrence in people of all ages, ... to offer to the discussion of dealing with excess skin oil. “Oily skin is a ... remedies that can help remove the oily shine while keeping the skin fresh and clean,” ...
(Date:3/28/2017)... ... ... and fungi are probably not the first ingredients that come to mind when thinking about ... your diet can actually improve health outcomes. And the good news is they may be ... new peer-reviewed paper led by Maria Marco, Ph.D. , University of California, ...
(Date:3/27/2017)... Ohio (PRWEB) , ... March 27, 2017 , ... New ... OH to replace their missing teeth can now have them placed by Dr. Manju ... the latest i-CAT® Cone Beam technology to increase the accuracy of each dental implant ...
(Date:3/27/2017)... TX (PRWEB) , ... March 27, 2017 , ... A ... Edward Buckingham MD, and his colleague, Sudeep Roy, MD, was recently published in ... Bipolar Electrocautery Efficacy in Rhytidectomy” details Drs. Buckingham and Roy’s study on the use ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... Summary This report provides all the information ... interests and activities since 2010. Description The Partnering Deals ... the partnering activity of one of the world,s leading life ... upon purchase to ensure inclusion of the most up to ... be delivered in PDF format within 1 working day of ...
(Date:3/27/2017)... VANCOUVER, British Columbia , March 27, 2017 /PRNewswire/ ... of Directors has appointed William "Bill" Dubiel as President ... Dubiel was also elected to the Board of Directors ... serve as the Executive Chairman of LightIntegra. ... become LightIntegra,s next President and Chief Executive Officer. We,ve ...
(Date:3/27/2017)... VANCOUVER, British Columbia, March 27, 2017  Sophiris ... "Company" or "Sophiris"), a clinical late-stage biopharmaceutical company ... with urological diseases, today reported fourth quarter and ... highlights. Key Corporate Highlights: ... for Localized Prostate Cancer. During 2016, the Company ...
Breaking Medicine Technology: